Can a targeted drug boost Chemotherapy's power against a rare lymphoma?
NCT ID NCT07753642
First seen Aug 07, 2026 · Last updated Aug 07, 2026
Summary
This trial is testing whether adding the targeted drug golidocitinib to standard chemotherapy can improve outcomes for people with a rare type of lymphoma called nodal T-follicular helper cell lymphoma. The study will include about 47 adults who have not yet received treatment for this disease. The main goal is to see how many patients achieve complete remission after the initial treatment, while also monitoring safety and long-term effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- golidocitinib combined with an anthracycline-based chemotherapy regimen (doxorubicin or epirubicin)
- What this could lead to
- If successful, this combination could become a new first-line treatment option for nodal TFH cell lymphoma, potentially improving remission rates and long-term outcomes.
- What could go wrong
- This is a phase II trial with a small number of participants, so results may not be conclusive. The combination may cause side effects, and its effectiveness compared to standard care is not yet established.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NODAL T-FOLLICULAR HELPER CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University
Guangzhou, Guangdong, 51000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.